Cooley, Davis Polk Tapped for Biotech IPO
PALO ALTO — Revance Therapeutics, Inc., a biotech company developing next-generation forms of Botox, has tapped a team from Cooley to smooth the path toward a projected $86 million initial public offering. Menlo Park–based attorneys from Davis Polk & Wardwell are advising underwriters.
This content has been archived. It is available exclusively through our partner LexisNexis®.
To view this content, please continue to Lexis Advance®.
Not a Lexis Advance® Subscriber? Subscribe Now
For questions call 1-877-256-2472 or contact us at email@example.com